Our Vision

GCANRx is a clinical stage biopharmaceutical company focused on the development and commercialization of an innovative pharma-grade therapeutic that reduces disruptive symptoms in patients suffering from neuropsychiatric disorders without the side effects of existing medications.

We are recruiting 100 participants (ages 4-13) for a 2-part, 24-week double-blind, placebo controlled study to prove the efficacy of a new therapeutic in treating the core symptoms of Autism (ASD).